Matthew Perry resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
XOMA Royalty Corp — fact timeline
Source-grounded facts extracted from XOMA Royalty Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Joseph M. Limber resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Barbara Kosacz resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Owen Hughes resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Natasha Hernday resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Heather L. Franklin resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Jack L. Wyszomierski resigned as Director at XOMA Royalty Corp.
“each of Jack L. Wyszomierski, Heather L. Franklin, Natasha Hernday, Owen Hughes, Barbara Kosacz, Joseph M. Limber and Matthew Perry, voluntarily resigned as directors of the Company”
Andrew Reardon was appointed as Director at XOMA Royalty Corp.
“the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company”
Octavio Espinoza was appointed as Director at XOMA Royalty Corp.
“the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company”
Todd C. Davis was appointed as Director at XOMA Royalty Corp.
“the directors of Merger Sub as of immediately prior to the Effective Time, Todd C. Davis, Octavio Espinoza and Andrew Reardon, became the directors of the Company”
XOMA Royalty Corp shareholders approved Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers.
“Proposal 5. Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers 8,330,043 76,630 10,759 695,090”
XOMA Royalty Corp shareholders approved Approval of the 2026 Employee Stock Purchase Plan.
“Proposal 4. Approval of the 2026 Employee Stock Purchase Plan 8,351,699 62,485 3,248 695,090”
XOMA Royalty Corp shareholders approved Approval of an Amendment and Restatement of the 2010 Long Term Incentive and Stock Award Plan.
“Proposal 3. Approval of an Amendment and Restatement of the 2010 Long Term Incentive and Stock Award Plan 7,738,322 668,915 10,195 695,090”
XOMA Royalty Corp shareholders approved Ratification of Selection of Deloitte & Touche LLP as Independent Auditor.
“Proposal 2. Ratification of Selection of Deloitte & Touche LLP as Independent Auditor 9,041,336 12,019 59,167 0”
XOMA Royalty Corp shareholders approved Election of Director Nominees.
“Proposal 1. Election of Director Nominees • Owen Hughes 8,339,874 77,558 695,090 • Jack L. Wyszomierski 8,330,001 87,431 695,090 • Heather L. Franklin 8,339,062 78,370 695,090 • Natasha Hernday 8,301,769 115,663 695,090 • Barbara Kosacz 8,332,787 84,645 695,090 • Joseph M. Limber 8,323,073 94,359 695,090 • Matthew D. Perry 8,343,711 73,721 695,090”
XOMA Royalty Corp: Amended bylaws to add Nevada controlling interest statutes language and an exclusive forum provision for state and federal securities law claims (effective 2026-05-21).
“the Board of Directors adopted and approved amendments to the Company’s bylaws (the “Bylaws”) to: (1) include language related to the Nevada controlling interest statutes, including Nevada Revised Statutes 78.378 through 78.3793, inclusive, to help clarify the applicability of these statutes, and (2) introduce an exclusive forum provision, which provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for certain state corporate law or stockholder derivative claims, and that the federal district courts shall be the sole and exclusive forum for any claim arising under the federal securities laws, in each case to the fullest extent permitted by law and unless the Company consents in writing to the selection of an alternative forum.”
XOMA Royalty Corp entered into Merger Agreement with Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (effective 2026-04-27).
“On April 27, 2026, XOMA Royalty Corporation, a Nevada corporation (the “ Company ” or “ XOMA Royalty ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Parent ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”)”
XOMA Royalty Corp reported financial results for the fiscal quarter and year ended December 31, 2025.
“On March 18, 2026, XOMA Royalty Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
XOMA Royalty Corp completed an acquisition involving Generation Bio Co. for $4.2913 per Company Share, payable in cash, plus one non-tradeable contingent value right per Company Share (closed 2026-02-09).
“offer to acquire all of Generation Bio’s issued and outstanding shares (the “ Company Shares ”) of common stock, par value $0.0001 per share (the “ Common Stock ”), for (i) $4.2913 per Company Share, payable in cash, without interest and less any applicable tax withholding (such amount, the “ Cash Amount ”), plus (ii) one non-tradeable contingent value right”
XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).
“XOMA acquired LAVA's EGFRd2 (PF-8046052), JNJ-89853413 and LAVA-1266 legacy assets”
XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).
“XOMA and LAVA effectuated the Post-Offer Reorganization, which became effective on November 20, 2025.”
XOMA Royalty Corp: Corrected a typographical error in Section 8(a) of the Certificate of Designation of 8.375% Series B cumulative perpetual preferred stock, changing '1.253.13' to '1,253.13' (effective 2025-09-23).
“On September 23, 2025, the Company filed a Certificate of Correction (the “ Certificate of Correction ”) to the Certificate of Designation of 8.375% Series B cumulative perpetual preferred stock originally filed with the Secretary of State of the State of Nevada on May 29, 2025 (the “ Certificate of Designation ”). The Certificate of Correction corrects a typographical error in Section 8(a) of the Certificate of Designation from “1.253.13” to “1,253.13”.”
XOMA Royalty Corp completed an acquisition involving Turnstone Biologics Corp. for $0.34 per share plus one non-transferable contractual contingent value right (closed 2025-08-11).
“2025, XOMA completed a tender offer to purchase all of Turnstone’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), for a price per Share of (i) $0.34 (the “ Cash Amount ”), payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right (“ CVR ”), which”
XOMA Royalty Corp shareholders approved Ratification of Selection of Deloitte & Touche LLP as Independent Auditor at the 2024-05-15 meeting.
“Proposal 2. Ratification of Selection of Deloitte & Touche LLP as Independent Auditor 7,872,497 5,250 50,848 ––”
XOMA Royalty Corp shareholders approved Election of Director Nominees at the 2024-05-15 meeting.
“Proposal 1. Election of Director Nominees • Heather L. Franklin 7,011,236 17,644 899,715 • Natasha Hernday 6,970,972 57,908 899,715 • Owen Hughes 7,009,858 19,022 899,715 • Barbara Kosacz 6,976,828 52,052 899,715 • Joseph M. Limber 7,002,628 26,252 899,715 • Matthew D. Perry 7,011,582 17,298 899,715 • Jack L. Wyszomierski 7,001,252 27,628 899,715”
XOMA Royalty Corp reported the quarter ended March 31, 2024 results: revenue $1.5 million, net income $8.6 million.
“XOMA recorded total revenues of $1.5 million for the first quarter of 2024, which included a $1.0 million milestone payment received from AVEO Oncology, as compared with $0.4 million in the first quarter of 2023.”
XOMA Royalty Corp completed an acquisition involving Kinnate Biopharma Inc. for $2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2024-04-03).
“April 3, 2024, XOMA completed a tender offer to purchase all of Kinnate’s outstanding shares of common stock, par value $0.0001 per share (the “ Shares ”), in exchange for (i) $2.5879 in cash per Share (the “ Cash Amount ”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “ CVR ” and each CVR together with the Cash Amount,”
XOMA Royalty Corp reported fourth quarter and full year 2023 results: net income net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.
“In 2023, net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.”
XOMA Royalty Corp reported fourth quarter and full year of 2023 results: revenue $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively, net income net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.
“XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.”
XOMA Royalty Corp entered into Merger Agreement with Kinnate Biopharma Inc. (effective 2024-02-16).
“On February 16, 2024, XOMA Corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kinnate Biopharma Inc., a Delaware limited liability company (“Kinnate”), and XRA 1 Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”).”
Owen Hughes was appointed as Chief Executive Officer at XOMA Royalty Corp.
“On January 7, 2024, the board of directors (the “Board”) of XOMA Corporation, a Delaware corporation (the “Company”), appointed Owen Hughes, previously Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer and to continue serving as principal executive officer and a director, effective immediately.”
XOMA Royalty Corp incurred credit facility of up to $140 million with Blue Owl Capital Inc. at 9.875% per annum maturing December 15, 2038.
“dated December 15, 2023, with the lenders from time to time party thereto (the “ Lenders ”) and Blue Owl Capital Corporation, as administrative agent (the “ Administrative Agent ”), pursuant to which the lenders extended certain senior secured credit facilities to the Subsidiary (the “ Loan ”) in an aggregate principal amount of up to $140 million (the “ Loan Amount ”).”
XOMA Royalty Corp entered into Warrants with Blue Owl Capital Inc. valued at warrants to purchase up to 120,000 shares of common stock at exercise prices of $35.00, $42.50, and (effective 2023-12-15).
“XOMA also issued to Blue Owl warrants (the “ Warrants ”), to purchase (i) up to 40,000 shares of XOMA’s common stock, par value $0.0075 (“ Common Stock ”) at an exercise price of $35.00 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.1; (ii) up to 40,000 shares of Common Stock at an exercise price of $42.50 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.2; and (iii) up to 40,000 shares of Common Stock at an exercise price of $50.00 per share, the form of which is attached to this Current Report on Form 8-K as Exhibit 4.3.”
XOMA Royalty Corp entered into Loan Agreement with Blue Owl Capital Corporation valued at up to $140 million principal amount; interest rate 9.875% per annum; maturity December 15, 2038 (effective 2023-12-15).
“On December 15, 2023, XOMA Corporation (“ XOMA ”), through XRL 1 LLC, a newly formed, wholly-owned subsidiary (the “ Subsidiary ”), entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital (the “ Royalty Financing ”) with certain funds managed by the credit platform of Blue Owl Capital Inc. (collectively, “ Blue Owl ”).”
XOMA Royalty Corp reported financial results for the third quarter of 2023.
“On November 7, 2023, XOMA Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
XOMA Royalty Corp terminated License Agreement (ebopiprant) with Organon International GmbH valued at Termination for convenience; no material penalties; Company to seek out-license (effective 2023-10-23).
“On October 23, 2023, Organon International GmbH (“Organon”), notified XOMA Corporation (the “Company”) of its intent to terminate for convenience that certain License Agreement, by and between Organon and ObsEva SA (“ObsEva”), dated July 26, 2021 (the “License Agreement”).”
XOMA Royalty Corp reported the quarter ended June 30, 2023 results: revenue total revenues of $1.7 million, net income Net loss for the second quarter of 2023 was $5.4 million.
“XOMA recorded total revenues of $1.7 million for the second quarter of 2023”
XOMA Royalty Corp entered into Royalty Purchase Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).
“On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.”
XOMA Royalty Corp entered into Assignment and Assumption Agreement with LadRx Corporation valued at $5 million upfront, up to $6 million in potential milestone payments (effective 2023-06-21).
“On June 21, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) and a Royalty Purchase Agreement (the “Royalty Purchase Agreement” and together with the Assignment Agreement, the “Agreements”) with LadRx Corporation (“LadRx”), a Delaware corporation.”
XOMA Royalty Corp shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation.
“The stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers based upon the following votes: 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTE 2,665,978 34,513 4,367,361 14,770 746,591”
XOMA Royalty Corp shareholders approved Advisory vote to approve named executive officer compensation.
“The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement based upon the following votes: FOR AGAINST ABSTAIN BROKER NON-VOTE 6,449,602 622,941 10,079 746,591”
XOMA Royalty Corp shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2023.
“The stockholders approved the ratification of Deloitte & Touche LLP to act as the Company’s independent registered public accounting firm for the 2023 fiscal year based upon the following votes: FOR AGAINST ABSTAIN BROKER NON-VOTE 7,787,958 14,671 26,584 N/A”
XOMA Royalty Corp shareholders approved Amendment of the Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 709,000 shares.
“The stockholders approved an amendment of the Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 709,000 shares based on the following votes: FOR AGAINST ABSTAIN BROKER NON-VOTE 6,918,099 161,547 2,976 746,591”
XOMA Royalty Corp shareholders approved Election of seven directors for a one-year term.
“Each of the seven nominees for election to the Board was elected to serve for a one-year term based upon the following votes: NAME FOR WITHHELD BROKER NON-VOTE Heather L. Franklin 7,068,387 14,235 746,591 Natasha Hernday 6,964,733 117,889 746,591 Owen Hughes 7,008,612 74,010 746,591 Barbara Kosacz 6,982,517 100,105 746,591 Joseph M. Limber 7,066,870 15,752 746,591 Matthew D. Perry 7,071,311 11,311 746,591 Jack L. Wyszomierski 6,914,994 167,628 746,591”
XOMA Royalty Corp reported first quarter of 2023 results: revenue $0.4 million, net income $9.8 million.
“XOMA recorded total revenues of $0.4 million for the first quarter of 2023, compared with $3.1 million in the first quarter of 2022.”
XOMA Royalty Corp entered into Payment Interest Purchase Agreement with Aptevo Therapeutics Inc. valued at $9.6 million (effective 2023-03-29).
“On March 29, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into a Payment Interest Purchase Agreement (the “Agreement”) with Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”).”
XOMA Royalty Corp reported the quarter and year ended December 31, 2022 results: revenue $1.5 million and $6.0 million, net income Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million.
“said Brad Sitko, Chief Investment Officer of XOMA. Fourth Quarter and Full Year 2022 Financial Results Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively. For the full year of 2022, XOMA’s reported revenues were related to milestone payments of $2.0 million from Rezolute, $0.8 million from Takeda,”
Owen Hughes was appointed as Interim Chief Executive Officer at XOMA Royalty Corp.
“appointed Owen Hughes as our Interim Chief Executive Officer and principal executive officer and as a member of our Board and Executive Chairman of our Board, effective as of January 1, 2023.”
XOMA Royalty Corp entered into Intellectual Property Acquisition Agreement with ObsEva SA valued at $15 million upfront plus up to $98 million in milestone payments (effective 2022-11-21).
“On November 21, 2022, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into an intellectual property acquisition agreement (the “Agreement”) with ObsEva, SA, a Swiss biotech company (“ObsEva”).”
XOMA Royalty Corp reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $4.2 million.
“XOMA recorded total revenues of $0.5 million for the third quarter of 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.